Why insider trading matters?
When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2021-03-15 | O'Driscoll Kathryn | Chief People Officer | Sell | 786 | $34.72 | $27,290 | Yes |
| 2021-03-10 | O'Driscoll Kathryn | Chief People Officer | Sell | 568 | $34.95 | $19,854 | Yes |
| 2021-03-10 | Polverino Anthony J. | Chief Scientific Officer | Sell | 1,048 | $34.95 | $36,631 | Yes |
| 2021-03-10 | Tehrani Ali | Chief Executive Officer | Sell | 4,392 | $34.95 | $153,516 | Yes |
| 2021-03-10 | HAUSMAN DIANA | Chief Medical Officer | Sell | 1,048 | $34.95 | $36,631 | Yes |
| 2020-12-09 | Klompas Neil A | Chief Financial Officer | Sell | 25,000 | $53.25 | $1,331,132 | No |
| 2020-12-09 | Klompas Neil A | Chief Financial Officer | Sell | 25,000 | $53.25 | $1,331,132 | Yes |
| 2020-12-07 | Tehrani Ali | Chief Executive Officer | Sell | 850 | $56.16 | $47,736 | No |
| 2020-12-04 | HAUSMAN DIANA | Chief Medical Officer | Sell | 6,032 | $55.12 | $332,476 | Yes |
| 2020-12-02 | HAUSMAN DIANA | Chief Medical Officer | Sell | 18,968 | $55.19 | $1,046,803 | Yes |
| 2020-11-02 | Tehrani Ali | Chief Executive Officer | Sell | 3,500 | $39.04 | $136,624 | No |
| 2020-09-14 | HAUSMAN DIANA | Chief Medical Officer | Sell | 40,000 | $45.00 | $1,800,000 | Yes |
| 2020-04-03 | Tehrani Ali | Chief Executive Officer | Buy | 575 | $33.39 | $19,199 | No |
| 2020-01-27 | Cox Troy | Director | Buy | 7,500 | $46.50 | $348,750 | No |
| 2019-05-06 | Poon David Kai Yuen | See Remarks | Sell | 800 | $19.20 | $15,360 | Yes |
| 2019-05-06 | Klompas Neil A | Chief Financial Officer | Sell | 8,308 | $19.23 | $159,733 | Yes |
| 2019-03-29 | Tehrani Ali | Chief Executive Officer | Sell | 3,000 | $16.24 | $48,720 | No |
| 2019-01-31 | LILLY ELI & CO | 10%-Owner | Sell | 250,000 | $16.00 | $4,000,000 | No |
| 2018-11-06 | LILLY ELI & CO | 10%-Owner | Sell | 700,000 | $14.00 | $9,800,000 | No |
| 2018-09-24 | LILLY ELI & CO | 10%-Owner | Sell | 2,027 | $16.36 | $33,162 | No |
| 2018-09-18 | LILLY ELI & CO | 10%-Owner | Sell | 6,870 | $14.56 | $100,027 | No |
| 2018-09-17 | LILLY ELI & CO | 10%-Owner | Sell | 15,874 | $14.58 | $231,443 | No |
| 2018-09-13 | LILLY ELI & CO | 10%-Owner | Sell | 30,959 | $14.49 | $448,463 | No |
| 2018-09-11 | LILLY ELI & CO | 10%-Owner | Sell | 15,777 | $14.75 | $232,669 | No |
| 2018-08-31 | LILLY ELI & CO | 10%-Owner | Sell | 700 | $14.26 | $9,982 | No |
| 2018-08-30 | LILLY ELI & CO | 10%-Owner | Sell | 5,752 | $14.31 | $82,333 | No |
| 2018-08-14 | LILLY ELI & CO | 10%-Owner | Sell | 3,000 | $14.28 | $42,840 | No |
| 2018-08-13 | LILLY ELI & CO | 10%-Owner | Sell | 6,429 | $14.32 | $92,033 | No |
| 2018-08-03 | LILLY ELI & CO | 10%-Owner | Sell | 1,650 | $13.55 | $22,358 | No |
| 2018-08-02 | LILLY ELI & CO | 10%-Owner | Sell | 19,400 | $13.31 | $258,214 | No |
Insider Smart
Insider Smart